Search

everythinglearnresearchcommunity

for

Search:↓

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.

Urinary PSA could be an early marker for enlarged prostate.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Finasteride reduces PSA levels by around 40-50% in BPH patients.

Baldness score can't be used to predict prostate size.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

No link found between hair loss severity and PSA levels in men.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Finasteride works better for hair loss in patients 26 or younger.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.

Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.